What are the side effects of Deucravacitinib?

Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor, mainly used to treat moderate to severe plaque psoriasis. Although it is more targeted and has milder side effects than traditional JAK inhibitors, there are still a series of adverse reactions that require attention, especially in patients who take the drug for a long time or have comorbidities.

From a pharmacological mechanism, deuterated coxitinib regulates inflammatory factors related to psoriasis (such as IL-23, IL-12 and type I interferon) by inhibiting the TYK2 signaling pathway, but it may also affect the body's immune balance. This means that some patients may develop upper respiratory tract infections such as nasopharyngitis, cough or mild bronchitis after taking the drug. Although most cases are mild to moderate and can resolve spontaneously, the state of immune system regulation still requires concern.

Regarding the digestive system, some patients may experience diarrhea, nausea, stomach upset, or mild liver function abnormalities. These phenomena are more common in the early stages of use and generally do not lead to treatment interruption. However, for people with chronic liver disease or a long history of drinking, it is recommended to closely monitor liver enzyme levels during use.

Skin reactions are also a type of side effect that cannot be ignored during the use of deuterated coxitinib. There are reports that some users may experience acne-like rashes, dryness, increased itching, or localized erythema. Although it targets immune pathways, modulation of individual immune responses may still lead to exacerbation of local skin inflammation, especially in patients with severe underlying skin lesions.

In addition, individual patients may also experience systemic discomforts such as mild headache, fatigue, joint pain, or decreased sleep quality. These symptoms are usually related to the initial adaptation period to medication and may gradually improve over several weeks. Compared with traditional systemic immunosuppressants or broad-spectrum JAK inhibitors, deuterated colexitinib does not show significant risks of serious infections, malignant tumors or cardiovascular events due to its high selectivity and is relatively better tolerated.

Reference materials:https://go.drugbank.com/drugs/DB16650